Fate Therapeutics, Inc. (FATE)

Over the past six months, Fate Therapeutics' stock has experienced a significant decline. The stock price passed below its 200-day moving average on November 28, 2025. Key events impacting the stock include earnings reports, mixed analyst ratings, positive clinical data from the FT819 program, and a strategic pivot towards autoimmune diseases.

Information directly addressing demand seasonality for Fate Therapeutics, Inc.'s products and services is not explicitly available. As a clinical-stage biopharmaceutical company, its revenue is primarily derived from collaboration activities and not from the commercial sale of approved products. The demand for its investigational therapies is driven by ongoing clinical trials and the progression of its pipeline, which is not typically subject to seasonal fluctuations.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. The company uses a proprietary induced pluripotent stem cell (iPSC) product platform to engineer off-the-shelf natural killer (NK) cell and T-cell product candidates. Key product candidates include FT819 for SLE and other B cell-mediated autoimmune diseases and cancer, FT522 for B-cell Lymphoma and autoimmunity, FT576 to treat multiple myeloma, FT825 targeting solid tumors, and FT836 for conditioning-free treatment of solid tumors.

Fate Therapeutics is headquartered in San Diego, California, United States, and its operations are global. The company conducts clinical trials internationally and collaborates with research institutions worldwide. It also has locations and subsidiaries in Canada, the United Kingdom, and the Netherlands.

Fate Therapeutics maintains a reputation as a clinical-stage biopharmaceutical company at the forefront of developing next-generation cellular immunotherapies. Events affecting its reputation include leadership changes, clinical progress and presentations, a strategic focus shift towards autoimmune diseases, regulatory interactions, and operational risks.

Fate Therapeutics, Inc.'s ownership is predominantly institutional, with institutional investors holding approximately 69% of the company's shares. Major institutional owners include Redmile Group, LLC, BlackRock, Inc., and Vanguard Group Inc. Retail/general public ownership is around 28.81%, and insiders hold about 2.17%.